{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T07:45:18Z","timestamp":1776584718172,"version":"3.51.2"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"1037","license":[{"start":{"date-parts":[[2014,3,26]],"date-time":"2014-03-26T00:00:00Z","timestamp":1395792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5,1]]},"abstract":"<jats:sec>\n                  <jats:title>Objective:<\/jats:title>\n                  <jats:p>This study is an analysis of the pre-trial quality assurance (QA) exercises submitted by clinicians from radiotherapy (RT) centres across Europe and Canada to qualify for participation in the CONVERT trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>QA exercises submitted by 64 clinicians at 64 RT centres were included in this analysis. The exercises included the completion of a trial-specific questionnaire and submission of a treatment plan, for both trial arms, for a patient fitting the eligibility criteria of the trial. This article describes the QA programme set up for the CONVERT trial and identifies deviations from the trial protocol. Patient eligibility, disease and critical structure outlining and treatment planning technique were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>Results from QA trial-specific questionnaires received between February 2008 and September 2011, returned as part of the QA exercise, indicated that the majority of centres (70.3%) were using 6-MV photons and type B treatment planning system algorithms (57.8%). 90.6% of clinicians assessed submitted data for patients who fitted the eligibility criteria for the trial. There were inconsistencies in outlining of gross tumour volume (GTV) and organs at risk, mainly heart and oesophagus, and in the use of margins around the GTV.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion:<\/jats:title>\n                  <jats:p>Such a QA programme helps to ensure that centres conform to trial protocol and should reduce inconsistencies in RT planning that may confound the results of the CONVERT trial.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge:<\/jats:title>\n                  <jats:p>Few studies reporting pre-trial QA have been published to date. This article outlines the importance of such a QA programme in the context of multicentre Phase III studies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1259\/bjr.20130653","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T09:09:12Z","timestamp":1394701752000},"source":"Crossref","is-referenced-by-count":17,"title":["Is pre-trial quality assurance necessary? Experiences of the CONVERT Phase III randomized trial for good performance status patients with limited-stage small-cell lung cancer"],"prefix":"10.1093","volume":"87","author":[{"given":"N","family":"Groom","sequence":"first","affiliation":[{"name":"Mount Vernon Cancer Centre, Northwood, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Wilson","sequence":"additional","affiliation":[{"name":"University College London Hospitals NHS Foundation Trust, London, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E","family":"Lyn","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba, Winnipeg, MB, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C","family":"Faivre-Finn","sequence":"additional","affiliation":[{"name":"The Christie NHS Foundation Trust, Manchester, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,3,26]]},"reference":[{"key":"2024050213550522500_b1","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1200\/JCO.1993.11.2.336","article-title":"Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group","volume":"11","author":"Murray","year":"1993","journal-title":"J Clin Oncol"},{"key":"2024050213550522500_b2","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1200\/JCO.1996.14.3.806","article-title":"Patients with limited-stage small-cell lung cancer treated with concurrent twice-daily chest radiotherapy and etoposide\/cisplatin followed by cyclophosphamide, doxorubicin, and vincristine","volume":"14","author":"Johnson","year":"1996","journal-title":"J Clin Oncol"},{"key":"2024050213550522500_b3","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1056\/NEJM199901283400403","article-title":"Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide","volume":"340","author":"Turrisi","year":"1999","journal-title":"N Engl J Med"},{"key":"2024050213550522500_b4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.lungcan.2008.06.013","article-title":"Radiotherapy for small-cell lung cancer\u2014where are we heading?","volume":"63","author":"Bayman","year":"2009","journal-title":"Lung Cancer"},{"key":"2024050213550522500_b5","unstructured":"CONVERT Trial Protocol (final version 3)\n.\n[updated 10 June 2008]. Available from:\n\u00a0http:\\\\www.converttrial.com"},{"key":"2024050213550522500_b6","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0360-3016(84)90460-7","article-title":"Radiotherapy quality assurance in clinical trials","volume":"10","author":"Perez","year":"1984","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b7","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.ejca.2012.02.008","article-title":"Development of clinical trial protocols involving advanced radiation therapy techniques: the European Organisation for Research and Treatment of Cancer Radiation Oncology Group approach","volume":"48","author":"Fairchild","year":"2012","journal-title":"Eur J Cancer"},{"key":"2024050213550522500_b8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0360-3016(98)00191-6","article-title":"A multidisciplinary study investigating radiotherapy in Ewing's sarcoma: end results of POG #8346. Pediatric Oncology Group","volume":"42","author":"Donaldson","year":"1998","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b9","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20120398","article-title":"Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case","volume":"86","author":"Gwynne","year":"2013","journal-title":"Br J Radiol"},{"key":"2024050213550522500_b10","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.radonc.2003.09.007","article-title":"Literature-based recommendations for treatment planning and execution in high-dose radiotherapy for lung cancer","volume":"71","author":"Senan","year":"2004","journal-title":"Radiother Oncol"},{"key":"2024050213550522500_b11","article-title":"Report 62: prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50)","author":"Landberg","year":"1999"},{"key":"2024050213550522500_b12","article-title":"Report 50: prescribing, recording and reporting photon beam therapy","author":"Landberg","year":"1993"},{"key":"2024050213550522500_b13","author":"Gianolini"},{"key":"2024050213550522500_b14","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1120\/jacmp.v3i1.2592","article-title":"Dosimetric advantage of using 6MV over 15MV photons in conformal therapy of lung cancer: Monte Carlo studies in patient geometries","volume":"3","author":"Wang","year":"2002","journal-title":"J Appl Clin Med Phys"},{"key":"2024050213550522500_b15","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.1016\/j.ijrobp.2007.07.2387","article-title":"Processes for quality improvements in radiation oncology clinical trials","volume":"71","author":"FitzGerald","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b16","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.ijrobp.2007.08.083","article-title":"Challenges in credentialing institutions and participants in advanced technology multi-institutional clinical trials","volume":"71","author":"Ibbott","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b17","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ijrobp.2007.07.2393","article-title":"Quality assurance issues in conducting multi-institutional advanced technology clinical trials","volume":"71","author":"Purdy","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b18","first-page":"197","volume-title":"Quality and safety in radiotherapy","author":"Purdy","year":"2011"},{"key":"2024050213550522500_b19","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1200\/JCO.2009.27.4498","article-title":"Critical impact of radiotherapy protocol compliance and quality in the treatment of advanced head and neck cancer: results from TROG 02.02","volume":"28","author":"Peters","year":"2010","journal-title":"J Clin Oncol"},{"key":"2024050213550522500_b20","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1093\/jnci\/djt001","article-title":"Radiotherapy protocol deviations and clinical outcomes: a meta-analysis of cooperative group clinical trials","volume":"105","author":"Ohri","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"2024050213550522500_b21","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1016\/j.ijrobp.2007.08.011","article-title":"Dose specification and quality assurance of Radiation Therapy Oncology Group protocol 95\u201317; a cooperative group study of iridium 192 breast implants as sole therapy","volume":"69","author":"Ibbott","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b22","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ijrobp.2011.12.080","article-title":"Redesigning radiotherapy quality assurance opportunities to develop an efficient, evidence based system to support clinical trials\u2014report of the National Cancer Institute work group on radiotherapy trials quality assurance","volume":"83","author":"Bekelman","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2024050213550522500_b23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.radonc.2011.05.073","article-title":"Quality assurance for prospective EORTC radiation oncology trials: the challenges of advanced technology in a multicentre international setting","volume":"100","author":"Weber","year":"2011","journal-title":"Radiother Oncol"}],"container-title":["The British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/87\/1037\/20130653\/57383982\/bjr.20130653.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/87\/1037\/20130653\/57383982\/bjr.20130653.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T14:01:23Z","timestamp":1714658483000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/doi\/10.1259\/bjr.20130653\/7445177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,26]]},"references-count":23,"journal-issue":{"issue":"1037","published-online":{"date-parts":[[2014,3,26]]},"published-print":{"date-parts":[[2014,5,1]]}},"URL":"https:\/\/doi.org\/10.1259\/bjr.20130653","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,5,1]]},"published":{"date-parts":[[2014,3,26]]},"article-number":"20130653"}}